Mohammed Abdul Rahman

This inventor holds 6 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Isp Investments Inc., Sartre Satire LLC, Other. Active years: 2006-2015.

USPTO Granted Patents = 6 (Patent Applications = 2)

% Patents Active = 66.7

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.4

ph-index = 3

Forward Citations = 31(Granted Patents)

Location History:

Pleasanton, CA (US) (2006 - 2012)
Columbia, MD (US) (2012)
Columbia, MA (US) (2015)

Company Filing History:

4 out of 834,411

Other

patents

Years Active: 2006-2015

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9114170 - Highly loaded amorphous efavirenz composition and process for preparing the same (2015-08-25),

2. 8313766 - Oral antidepressant formulation with reduced excipient load (2012-11-20),

3. RE43218 - Circuit and method for processing communication packets and valid data bytes (2012-02-27),

4. 7643517 - Method and circuit for de-skewing data in a communication system (2010-01-05),

5. 7130317 - Method and circuit for de-skewing data in a communication system (2006-10-31),

6. 7068673 - Circuit and method for processing communication packets and valid data bytes (2006-06-27),

Title: Innovations by Mohammed Abdul Rahman

Introduction

Mohammed Abdul Rahman is a notable inventor based in Columbia, MD (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug formulations. With a total of 6 patents to his name, his work focuses on enhancing the efficacy and stability of pharmaceutical compositions.

Latest Patents

Among his latest patents is a highly loaded amorphous efavirenz composition and the process for preparing it. This invention features a stable and high loading ternary solid dispersion composition that includes amorphous Efavirenz, polyvinyl pyrrolidone (PVP), and a water-soluble second polymer. Additionally, he has developed an oral antidepressant formulation that reduces the excipient load while maintaining the effectiveness of the active pharmaceutical ingredient, 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide.

Career Highlights

Throughout his career, Mohammed Abdul Rahman has worked with various companies, including Isp Investments Inc. His innovative approaches to drug formulation have positioned him as a key figure in the pharmaceutical industry.

Collaborations

He has collaborated with notable professionals in his field, including Andy P Annadurai and Feng Han. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Mohammed Abdul Rahman's contributions to pharmaceutical innovations demonstrate his commitment to improving drug formulations and patient outcomes. His work continues to influence the industry and inspire future advancements in pharmaceutical science.